Immunic, Inc. (IMUX) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Company performance

Add to research

Description

Add to research

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Metrics

Add to research

Overview

HQNew York, NY
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerIMUX
PriceN/A

Trading Information

Market cap$79.54M
Float96.59%
Average Daily Volume (1m)1,650,360
Average Daily Volume (3m)1,743,644
EPS-$0.98

Company

RevenueN/A
Rev growth (1yr)N/A
Net income-$25.47M
Gross marginN/A
EBITDA marginN/A
EBITDA-$26.78M

EV$97.14M
EV/RevenueN/A
P/EN/A
P/SN/A
P/BN/A
Debt/EquityN/A

Documents

Add to research

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q1

Earnings Report (2023-11-14)

Earnings Report (2023-08-06)

Factset

Factset Business Description

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Immunic Q3 (2023-11-21T15:49:44Z)

Immunic reports Q3 EPS ($0.51) vs FactSet ($0.55) [4 est, ($0.58)-(0.51)] ($0.97, 0.00) (2023-11-14T11:31:50Z)

Immunic reports positive interim data from Phase 2 CALLIPER trial of Vidofludimus calcium in progressive multiple sclerosis; webcast on 10-Oct-23 at 8:00 ET ($1.56, 0.00) (2023-10-09T20:09:27Z)

Immunic receives notice of allowance for US patent protecting the treatment of relapsing MS with vidofludimus ($1.04, 0.00) (2023-11-02T10:46:35Z)

Immunic receives Notice of Allowance for U.S. patent protecting Vidofludimus Calcium's dosing regimens in multiple sclerosis ($1.11, 0.00) (2023-11-21T11:32:53Z)